{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+B-Cell+Non-Hodgkin+Lymphoma&page=2", "query": { "condition": "Relapsed B-Cell Non-Hodgkin Lymphoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 1059, "total_pages": 106, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+B-Cell+Non-Hodgkin+Lymphoma&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+B-Cell+Non-Hodgkin+Lymphoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T05:49:55.022Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00951626", "title": "A Standardized Nursing Intervention Protocol for HCT Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Psychosocial Effects of Cancer and Its Treatment", "Therapy-related Toxicity" ], "interventions": [ { "name": "exercise intervention", "type": "BEHAVIORAL" }, { "name": "telephone-based intervention", "type": "BEHAVIORAL" }, { "name": "dietary intervention", "type": "DIETARY_SUPPLEMENT" }, { "name": "educational intervention", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "assessment of therapy complications", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "standard follow-up care", "type": "PROCEDURE" } ], "intervention_types": [ "BEHAVIORAL", "DIETARY_SUPPLEMENT", "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 282, "start_date": "2005-09", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-10-03T05:49:55.022Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00951626" }, { "nct_id": "NCT00952185", "title": "Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Nonmalignant Neoplasm", "Viral Infection" ], "interventions": [ { "name": "cytology specimen collection procedure", "type": "OTHER" }, { "name": "fluorescent antibody technique", "type": "OTHER" }, { "name": "assessment of therapy complications", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2008-11", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-10-03T05:49:55.022Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00952185" }, { "nct_id": "NCT04300998", "title": "Study of CAR-T Therapy in Older Patients", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma", "Refractory B-Cell Lymphoma", "Lymphoma, B-Cell", "DLBCL NOS", "High-grade B-cell Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "Activities of Daily Living/ADLs", "type": "BEHAVIORAL" }, { "name": "Instrumental Activity of Daily Living", "type": "BEHAVIORAL" }, { "name": "Timed Up and Go", "type": "BEHAVIORAL" }, { "name": "Cognition", "type": "BEHAVIORAL" }, { "name": "Geriatric Depression Scale", "type": "BEHAVIORAL" }, { "name": "Social Support", "type": "BEHAVIORAL" }, { "name": "Brief Test of Attention", "type": "BEHAVIORAL" }, { "name": "Trail Making Test", "type": "BEHAVIORAL" }, { "name": "Controlled Oral Word Association Test", "type": "BEHAVIORAL" }, { "name": "Hopkins Verbal Learning Test-Revised", "type": "BEHAVIORAL" }, { "name": "Blood draw", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 154, "start_date": "2020-03-04", "completion_date": "2027-03-04", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-10-03T05:49:55.022Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04300998" }, { "nct_id": "NCT05583149", "title": "Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Aggressive B-cell Lymphomas", "Refractory B-Cell Non-Hodgkin Lymphoma", "Aggressive B-cell NHL", "Diffuse Large B-cell Lymphoma (DLBCL)", "De Novo or Transformed Indolent B-cell Lymphoma", "DLBCL, Nos Genetic Subtypes", "T Cell/Histiocyte-rich Large B-cell Lymphoma", "EBV-Positive DLBCL, Nos", "Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL)", "High-Grade B-Cell Lymphoma, Nos", "C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma", "Grade 3b Follicular Lymphoma", "C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma" ], "interventions": [ { "name": "ACALABRUTINIB", "type": "DRUG" }, { "name": "LISOCABTAGENE MARALEUCEL", "type": "DRUG" }, { "name": "Lymphodepleting chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Patrick C. Johnson, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2023-03-01", "completion_date": "2029-03-01", "has_results": true, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-10-03T05:49:55.022Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05583149" }, { "nct_id": "NCT03846427", "title": "Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Marginal Zone Lymphoma", "MZL" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2019-02-19", "completion_date": "2022-05-04", "has_results": true, "last_update_posted_date": "2024-10-26", "last_synced_at": "2026-10-03T05:49:55.022Z", "location_count": 2, "location_summary": "Westbury, New York • Charlotte, North Carolina", "locations": [ { "city": "Westbury", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03846427" }, { "nct_id": "NCT06287229", "title": "Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory", "B-cell Acute Lymphocytic Leukemia" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Inotuzumab Ozogamicin", "type": "DRUG" }, { "name": "Hyper-CVAD", "type": "DRUG" }, { "name": "Mini-hyper-CVD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2024-07-11", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-03T05:49:55.022Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06287229" }, { "nct_id": "NCT00060372", "title": "Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Childhood Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Disseminated Neuroblastoma", "Malignant Neoplasm", "Ovarian Choriocarcinoma", "Ovarian Embryonal Carcinoma", "Ovarian Immature Teratoma", "Ovarian Mature Teratoma", "Ovarian Mixed Germ Cell Tumor", "Ovarian Monodermal and Highly Specialized Teratoma", "Ovarian Polyembryoma", "Ovarian Yolk Sac Tumor", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Neuroblastoma", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage II Ovarian Epithelial Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Multiple Myeloma", "Stage III Ovarian Epithelial Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Ovarian Epithelial Cancer", "Testicular Choriocarcinoma", "Testicular Choriocarcinoma and Embryonal Carcinoma", "Testicular Choriocarcinoma and Seminoma", "Testicular Choriocarcinoma and Teratoma", "Testicular Choriocarcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma", "Testicular Embryonal Carcinoma and Seminoma", "Testicular Embryonal Carcinoma and Teratoma", "Testicular Embryonal Carcinoma and Teratoma With Seminoma", "Testicular Embryonal Carcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma", "Testicular Teratoma", "Testicular Yolk Sac Tumor", "Testicular Yolk Sac Tumor and Teratoma", "Testicular Yolk Sac Tumor and Teratoma With Seminoma" ], "interventions": [ { "name": "ipilimumab", "type": "DRUG" }, { "name": "therapeutic allogeneic lymphocytes", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-03-27", "last_synced_at": "2026-10-03T05:49:55.022Z", "location_count": 5, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060372" }, { "nct_id": "NCT03990961", "title": "Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B Cell Lymphoma", "Lymphoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2019-09-04", "completion_date": "2024-04-01", "has_results": true, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-10-03T05:49:55.022Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03990961" }, { "nct_id": "NCT01094860", "title": "Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Nelarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 29, "start_date": "2010-06-08", "completion_date": "2018-08-09", "has_results": false, "last_update_posted_date": "2020-02-11", "last_synced_at": "2026-10-03T05:49:55.022Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01094860" }, { "nct_id": "NCT02928510", "title": "Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Absence of Signs or Symptoms", "B-Cell Non-Hodgkin Lymphoma", "Digestive System Signs and Symptoms", "Indolent Adult Non-Hodgkin Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Indolent Adult Non-Hodgkin Lymphoma", "Recurrent Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Colonoscopy", "type": "PROCEDURE" }, { "name": "Colposcopic Biopsy", "type": "PROCEDURE" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Physical Examination", "type": "PROCEDURE" }, { "name": "Sigmoidoscopy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2016-02-01", "completion_date": "2018-06-05", "has_results": false, "last_update_posted_date": "2021-07-14", "last_synced_at": "2026-10-03T05:49:55.022Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02928510" } ] }